Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 6/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 8/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
| ▸ | PI4KA | P42356 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.34 |
| ▸ | G6PD | P11413 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28867703 | 0.83 | PTPN11 (0.38) | MAP4K4PTPN11EGFRPDE10AKCNH2 | |
| SCHEMBL15981926 | 0.82 | MAP4K4 (0.42) | MAP4K4PIK3CDPIP5K1CPIK3CAPIK3CB | |
| SCHEMBL2949290 | 0.81 | MAP4K4 (0.41) | MAP4K4PIK3CDPIP5K1CPIK3CAPIK3CB | |
| SCHEMBL2038848 | 0.81 | MAP4K4 (0.41) | MAP4K4PIK3CDPIP5K1CPIK3CAPIK3CB | |
| SCHEMBL5437179 | 0.81 | MAP4K4 (0.41) | MAP4K4PTPN11PIK3CDPIP5K1CPIK3CA | |
| SCHEMBL4502318 | 0.81 | KCNH2 (0.43) | PTPN11EGFRKCNH2 | |
| SCHEMBL14905348 | 0.81 | EGFR (0.41) | MAP4K4PTPN11EGFRPDE10AKCNH2 | |
| SCHEMBL31391938 | 0.79 | MAP4K4 (0.38) | MAP4K4PTPN11PIK3CDPIP5K1CPIK3CA | |
| SCHEMBL29050347 | 0.79 | MAP4K4 (0.38) | MAP4K4PTPN11PIK3CDPIP5K1CPIK3CA | |
| SCHEMBL29698555 | 0.79 | MAP4K4 (0.38) | MAP4K4PTPN11PIK3CDPIP5K1CPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131444-A1 | Aminopiperidine Quinolines and Their Azaisosteric Analogues with Antibacterial Activity | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| EP-1891078-A1 | AMINOPIPERIDINE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY | AstraZeneca AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006125974-A1 | AMINOPIPERIDINE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131444-A1 | Aminopiperidine Quinolines and Their Azaisosteric Analogues with Antibacterial Activity | AAAS, AMPD2, AMPD3 | MAP4K4 2030/4885PTPN11 3293/4885PIK3CD 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.